News Column

Investigators from Yang Ming National University Report New Data on Ultrasound

February 14, 2014



By a News Reporter-Staff News Editor at Drug Week -- Investigators discuss new findings in Ultrasound. According to news reporting originating in Taipei, Taiwan, by NewsRx journalists, research stated, "Nanobubbles can serve as promising, next-generation theranostic platforms for ultrasound (US) and magnetic resonance (MR) imaging, and combined magnetic targeting (MT) and high-intensity focused ultrasound (HIFU)-triggered drug release for tumor therapy. Nanobubble-based dual contrast enhancement agents encapsulated with perfluoropentane and stabilized with superparamagnetic iron oxide (SPIO) nanoparticles have been synthesized through a single-step emulsion process from thermosensitive F127 and polyacrylic acid (PAA)."

The news reporters obtained a quote from the research from Yang Ming National University, "Both US and MR imaging contrast can be optimized by varying the shell thickness and SPIO-embedded concentration. The US contrast can be enhanced from a mean gray value of 62 to 115, and the MR r(2) value can be enhanced from 164 to 208 (s(-1) mM(-1) Fe) by increasing the SPIO concentration from 14.1 to 28.2 mg/mL, respectively. In vivo investigations of SPIO-embedded nanobubbles in excised tumors under external MT revealed that the US and MR signals change quantitatively compared to the same site without MT. This combined strategy enables the nanobubbles to enhance both passive targeting (increasing the permeability by HIFU) and physical MT of chemotherapeutic drugs to tumors."

According to the news reporters, the research concluded: "The integration of functionalities makes this nanobubble system a powerful and viable new tool to achieve simultaneous in vivo tumor imaging and efficacious cancer therapy."

For more information on this research see: SPIO nanoparticle-stabilized PAA-F127 thermosensitive nanobubbles with MR/US dual-modality imaging and HIFU-triggered drug release for magnetically guided in vivo tumor therapy. Journal of Controlled Release, 2013;172(1):118-127. Journal of Controlled Release can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; Journal of Controlled Release - www.elsevier.com/wps/product/cws_home/502690)

Our news correspondents report that additional information may be obtained by contacting H.Y. Huang, Yang Ming National University, Dept. of Biomed Engn, Taipei 112, Taiwan. Additional authors for this research include S.H. Hu, S.Y. Hung, C.S. Chiang, H.L. Liu, T.L. Chiu, H.Y. Lai, Y.Y. Chen and S.Y. Chen (see also Ultrasound).

Keywords for this news article include: Asia, Taipei, Taiwan, Therapy, Ultrasound

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Drug Week


Story Tools